The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. Many investors ...

We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

Qualcomm generated earnings of $3.41 a share in the latest quarter, versus Wall Street’s estimate for $2.96.